Revolution Medicines (RVMD) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price targets for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $47.00. On average, they anticipate the company's stock price to reach $35.57 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.

Revolution Medicines' stock was trading at $23.82 at the beginning of the year. Since then, RVMD stock has increased by 3.0% and is now trading at $24.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our RVMD earnings forecast.

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Tuesday, August, 8th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.10. The company earned $3.82 million during the quarter, compared to analyst estimates of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 36.46%. The business's revenue for the quarter was down 58.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) earnings per share.

ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

(RVMD) raised $150 million in an initial public offering (IPO) on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RVMD stock can currently be purchased for approximately $24.53.

Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $2.68 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.

The company employs 292 workers across the globe.

Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.